



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michael A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Lawrence B. Bugaisky
Michael V. Messinger
Judith U. Kim

Patrick E. Garrett
Jeffrey T. McVey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Albert L. Ferro
Donald R. Benowitz
Peter A. Jackman
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Brian J. Del Buono
Vigil Lee Beaton
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhuillier

Rae Lynn P. Guest
George S. Bardmesser
Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamege
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Aric W. Ledford
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth
Lori A. Gordon
Nicole D. Dretar
Ted J. Ebersole
Jyoti C. Iyer

Laura A. Vogel
Michael J. Mancuso
Bryan S. Wade
Aaron L. Schwartz
Michael G. Penn
Matthew E. Kelley
Shannon A. Carroll
Nicole R. Kramer

Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Cotella
Jeffrey S. Lundgren
Victoria S. Rutherford

Michelle K. Holoubek
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse
Christopher J. Walsh
Liliana Di Nola-Baron
Peter A. Socarras

Of Counsel
Kenneth C. Bass III
Evan R. Smith
Marvin C. Guthrie
*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

April 11, 2005

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Mail Stop Amendment
Art Unit: 1644
Schwadron, Ronald B.
Confirmation No.: 8008

WRITER'S DIRECT NUMBER:
(202) 772-8582
INTERNET ADDRESS:
PJACKMAN@SKGF.COM

Re: U.S. Utility Patent Application
Application No. 09/350,401; Filed: July 8, 1999
For: **Inducing Cellular Immune Responses to Hepatitis B Virus Using
Peptide and Nucleic Acid Compositions**
Inventors: SETTE *et al.*
Our Ref: 2060.0060008/PAJ/M-M

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Third Supplemental Information Disclosure Statement;
2. PTO Form 1449 citing ninety-eight (98) documents;
3. Copies of ninety (90) cited documents;
4. Fourth Supplemental Information Disclosure Statement;
5. PTO Form 1449 citing forty-four (44) documents;
6. Copies of thirty-five (35) cited documents; and
7. One (1) return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
April 11, 2005
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Peter A. Jackman", with a horizontal line drawn through it.

Peter A. Jackman
Attorney for Applicants
Registration No. 45,986

PAJ/M-M/slp:awt
Enclosures

381699_1.DOC



FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT

APPLICANT(S)

SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644

-U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA100	4,235,877	11/25/1980	Fullerton			06/27/1979
	AB100	4,487,715	12/11/1984	Nitecki <i>et al.</i>			07/09/1982
	AC100	4,599,230	07/08/1986	Milich <i>et al.</i>			03/09/1984
	AD100	4,837,028	06/06/1989	Allen			12/24/1986
	AE100	5,013,548	05/07/1991	Haynes <i>et al.</i>			01/21/1988
	AF100	5,128,319	07/07/1992	Arlinghaus			09/20/1989
	AG100	5,736,142	04/07/1998	Sette <i>et al.</i>			09/14/1994
	AH100	5,783,567	07/21/1998	Hedley <i>et al.</i>			01/22/1997
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL100	EP 0 378 881	06/09/1993	Europe			Yes No
	AM100	EP 0 429 816	06/05/1991	Europe			Yes No
	AN100	EP 0 433 242	06/19/1991	Europe			Yes No
	AO100	WO 93/03764	03/04/1993	WIPO			Yes No
	AP100	WO 94/20127	09/15/1994	WIPO			Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	100	Alexander, J., <i>et al.</i> , "Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides," <i>Immunity</i> 1:751-761, Cell Press (1994)
	AS	100	Arndt, S.O., <i>et al.</i> , "Selection of the MHC Class II-Associated Peptide Repertoire by HLA-DM," <i>Immunol. Res.</i> 16:261-272, Humana Press (December 1997)
	AT	100	Barouch, D., <i>et al.</i> , "HLA-A2 Subtypes Are Functionally Distinct in Peptide Binding and Presentation," <i>J. Exp. Med.</i> 182:1847-1856, Rockefeller University Press (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

THIRD SUPPLEMENTAL INFORMATION
STATEMENTATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL101	WO 95/07707 ✓	03/23/1995	WIPO			Yes No
	AM101	WO 96/22067 ✓	07/25/1996	WIPO			Yes No
	AN101	WO 97/41440 ✓	11/06/1997	WIPO			Yes No
	AO101	WO 97/34617 ✓	09/25/1997	WIPO			Yes No
	AP101	WO 01/00225 ✓	01/04/2001	WIPO			Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>101</u>	Bender, A., <i>et al.</i> , "Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood," <i>J. Immunol. Methods</i> 196:121-135, Elsevier Science (1996)
	AS	<u>101</u>	Ben-Yedidia, T., and Arnon, R., "Design of peptide and polypeptide vaccines," <i>Curr. Opin. Biotechnol.</i> 8:442-448, Current Biology, Ltd. (1997)
	AT	<u>101</u>	Carbone, F.R., and Bevan, M.J., "Induction of Ovalbumin-Specific Cytotoxic T Cells by In Vivo Peptide Immunization," <i>J. Exp. Med.</i> 169:603-612, Rockefeller University Press (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

THIRD SUPPLEMENTAL INFORMATION
STATEMENTATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL102	WO 98/32456	07/30/98	WIPO			Yes No
	AM102	WO 99/58658	11/18/99	WIPO			Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	102	Carbone, F.R., <i>et al.</i> , "Induction of Cytotoxic T Lymphocytes by Primary In Vitro Stimulation with Peptides," <i>J. Exp. Med.</i> 167:1767-1779, Rockefeller University Press (1988)
	AS	102	Cassell, D., and Forman, J., "Linked Recognition of Helper and Cytotoxic Antigenic Determinants for the Generation of Cytotoxic T Lymphocytes," <i>Ann. N.Y. Acad. Sci.</i> 532:51-60, New York Academy Of Sciences (1991)
	AT	102	Deres, K., <i>et al.</i> , "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine," <i>Nature</i> 342:561-564, Nature Publishing Group (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>103</u>	del Guercio, M-F., <i>et al.</i> , "Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T Helper Epitopes (PADRE) for antibody responses <i>in vivo</i> ," <i>Vaccine</i> 15:441-448, Elsevier Science (March 1997)
	AS	<u>103</u>	DiBrino, M., <i>et al.</i> , "Endogenous Peptides with Distinct Amino Acid Anchor Residue Motifs Bind to HLA-A1 and HLA-B8," <i>J. Immunol.</i> 152:620-631, American Association of Immunologists (1994)
	AT	<u>103</u>	DiBrino, M., <i>et al.</i> , "The HLA-B14 Peptide Binding Site Can Accommodate Peptides with Different Combinations of Anchor Residues," <i>J. Biol. Chem.</i> 269:32426-32434, American Society for Biochemistry and Molecular Biology (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>104</u>	Donnelly, J.J., <i>et al.</i> , "DNA Vaccines," <i>Annu. Rev. Immunol.</i> 15:617-648, Annual Reviews Inc. (April 1997)
	AS	<u>104</u>	Francis, M.J., <i>et al.</i> , "Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants," <i>Nature</i> 330:168-170, Nature Publication Group (1987)
	AT	<u>104</u>	Fynan, E.F., <i>et al.</i> , "DNA vaccines: Protective immunizations by parental, mucosal, and gene-gun inoculations," <i>Proc. Natl. Acad. Sci. USA</i> 90:11478-11482, National Academy of Sciences (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>105</u>	Gileadi, U., <i>et al.</i> , "Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes," <i>Eur. J. Immunol.</i> 29:2213-2222, WILEY-VCH Verlag GmbH (July 1999)
	AS	<u>105</u>	Golvano, J., <i>et al.</i> , "Polarity of immunogens: implications for vaccine design," <i>Eur. J. Immunol.</i> 20:2363-2366, VCH Verlagsgesellschaft mbH (1990)
	AT	<u>105</u>	Gulukota, K., <i>et al.</i> , "Two Complementary Methods for Predicting Peptides Binding Major Histocompatibility Complex Molecules," <i>J. Mol. Biol.</i> 267:1258-1267, Academic Press Limited (April 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>106</u>	Hahn, Y.S., <i>et al.</i> , "CD8 ⁺ T Cell Recognition of an Endogenously Processed Epitope is Regulated Primarily by Residues within the Epitope," <i>J. Exp. Med.</i> 176:1335-1341, Rockefeller University Press (1992)
	AS	<u>106</u>	Hahn, Y.S., <i>et al.</i> , "Presentation of Viral Antigen to Class I Major Histocompatibility Complex-Restricted Cytotoxic T Lymphocyte. Recognition of an Immunodominant Influenza Hemagglutinin Site by Cytotoxic T Lymphocyte is Independent of the Position of the Site in the Hemagglutinin Translation Product," <i>J. Exp. Med.</i> 174:733-736, Rockefeller University Press (1991)
	AT	<u>106</u>	Hammer, J., <i>et al.</i> , "Precise Prediction of Major Histocompatibility Complex Class II-Peptide Interaction Based on Peptide Side Chain Scanning," <i>J. Exp. Med.</i> 180:2353-2358, Rockefeller University Press (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>107</u>	Hill, C.M., <i>et al.</i> , "Exploration of Requirements for Peptide Binding to HLA DRB1*0101 and DRB1*0401," <i>J. Immunol.</i> 152:2890-2898, American Association of Immunologists (1994)
	AS	<u>107</u>	Huczko, E.L., <i>et al.</i> , "Characteristics of Endogenous Peptides Eluted from the Class I MHC Molecule HLA-B7 Determined by Mass Spectrometry and Computer Modeling," <i>J. Immunol.</i> 151:2572-2587, American Association of Immunologists (1993)
	AT	<u>107</u>	Ishioka, G.Y., <i>et al.</i> , "Class I MHC-restricted, peptide specific cytotoxic T lymphocytes generated by peptide priming in vivo," in <i>Vaccines90: Modern Approaches to New Vaccines Including Prevention of AIDS</i> , Brown, F., <i>et al.</i> , eds., Cold Spring harbor Laboratory Press, Cold Spring Harbor, NY, pp. 7-11 (1990)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>108</u>	Ishioka, G.Y., <i>et al.</i> , "Induction of Class I MHC-Restricted, Peptide-Specific Cytolytic T Lymphocytes by Peptide Priming In Vivo," <i>J. Immunol.</i> 143:1094-1100, American Association of Immunologists (1989)
	AS	<u>108</u>	Jardetzky, T.S., <i>et al.</i> , "Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding," <i>EMBO J.</i> 9:1797-1803, Oxford University Press (1990)
	AT	<u>108</u>	Kast, W.M., <i>et al.</i> , "Protection against lethal Sendai virus infection by <i>in vivo</i> priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide," <i>Proc. Natl. Acad. Sci. USA</i> 88:2283-2287, National Academy of Sciences (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>109</u>	Kondo, A., <i>et al.</i> , "Two distinct <i>HLA-A*0101</i> -specific submotifs illustrate alternative peptide binding modes," <i>Immunogenetics</i> 45:249-258, Springer-Verlag (January 1997)
	AS	<u>109</u>	Kubitscheck, U., <i>et al.</i> , "Peptide Binding to Class I Molecules of the Major Histocompatibility Complex on the Surface of Living Target Cells," <i>Scand. J. Immunol.</i> 36:341-348, Blackwell Scientific Publications (1992)
	AT	<u>109</u>	Kubo, R.T., <i>et al.</i> , "Definition of Specific Peptide Motifs for Four Major HLA-A Alleles," <i>J. Immunol.</i> 152:3913-3924, American Association of Immunologists (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>110</u>	Kumar, A., <i>et al.</i> , "Universal T Helper Cell Determinants Enhance Immunogenicity of a <i>Plasmodium falciparum</i> Merozoite Surface Antigen Peptide," <i>J. Immunol.</i> 148:1499-1505, American Association of Immunologists (1992)
	AS	<u>110</u>	Lasarte, J-J., <i>et al.</i> , "Induction of Cytotoxic T Lymphocytes in Mice against the Principal Neutralizing Domain of HIV-1 by Immunization with an Engineered T-Cytotoxic-T-Helper Synthetic Helper Peptide Construct," <i>Cell. Immunol.</i> 141:211-218, Academic Press Inc. (1992)
	AT	<u>110</u>	Madden, D.R., <i>et al.</i> , "The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation," <i>Nature</i> 353:321-325, Nature Publishing Group (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>111</u>	Maier, R., <i>et al.</i> , "Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing," <i>Immunogenetics</i> 40:306-308, Springer-Verlag (1994)
	AS	<u>111</u>	Martinon, F., <i>et al.</i> , "Immunization of Mice with Lipopeptides Bypasses the Prerequisite for Adjuvant," <i>J. Immunol.</i> 149:3416-3422, American Association of Immunologists (1992)
	AT	<u>111</u>	Niedermann, G., <i>et al.</i> , "Contribution of Proteasome-Mediated Proteolysis to the Hierarchy of Epitopes Presented by Major Histocompatibility Complex Class I Molecules," <i>Immunity</i> 2:289-299, Cell Press (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>112</u>	Niedermann, G., <i>et al.</i> , "The specificity of proteasomes: impact on MHC class I processing and presentation of antigens," <i>Immunol. Rev.</i> 172:29-48, Munksgaard (December 1999)
	AS	<u>112</u>	Nikolić-Žugić, J., and Carbone, F.R., "Peptide Presentation by Class-I Major Histocompatibility Complex Molecules," <i>Immunol. Res.</i> 10:54-65, S. Karger AG (1991)
	AT	<u>112</u>	O'Sullivan, D., <i>et al.</i> , "Characterization of the Specificity of Peptide Binding to Four DR Haplotypes," <i>J. Immunol.</i> 145:1799-1808, American Association of Immunologists (1990)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>113</u>	O'Sullivan, D., <i>et al.</i> , "On the Interaction of Promiscuous Antigenic Peptides with Different DR Alleles," <i>J. Immunol.</i> 147:2663-2669, American Association of Immunologists (1991)
	AS	<u>113</u>	Panina-Bordignon, P., <i>et al.</i> , "Universally immunogenic T cell eptiopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells," <i>Eur. J. Immunol.</i> 19:2237-2242, VCH Verlagsgesellschaft mbH (1989)
	AT	<u>113</u>	Paz, P., <i>et al.</i> , "Discrete Proteolytic Intermediates in the MHC Class I Antigen Processing Pathway and MHC I-Dependent Peptide Trimming in the ER," <i>Immunity</i> 11:241-251, Cell Press (August 1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	114	Penna, A., <i>et al.</i> , "Cytotoxic T Lymphocytes Recognize an HLA-A2-Restricted Epitope Within the Hepatitis B Virus Nucleocapsid Antigen," <i>J. Exp. Med.</i> 174:1565-1570, Rockefeller University Press (1991)
	AS	114	Pryjma, J., <i>et al.</i> , "Induction and Suppression of Immunoglobulin Synthesis in Cultures of Human Lymphocytes: Effects of Pokeweed Mitogen and <i>Staphylococcus Aureus</i> Cowan I," <i>J. Immunol.</i> 124:656-661, Williams & Wilkins Co. (1980)
	AT	114	Rahemtulla, A., <i>et al.</i> , "Normal development and function of CD8 ⁺ cells but markedly decreased helper cell activity in mice lacking CD4," <i>Nature</i> 353:180-183, Nature Publishing Group (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>115</u>	Rammensee, H-G., <i>et al.</i> , "SYFPEITHI: database for MHC ligands and peptide motifs," <i>Immunogenetics</i> 50:213-219, Springer-Verlag (November 1999)
	AS	<u>115</u>	Reitermann, A., <i>et al.</i> , "Lipopeptide Derivatives of Bacterial Lipoprotein Constitute Potent Immune Adjuvants Combined with or Covalently Coupled to Antigen or Hapten," <i>Biol. Chem. Hoppe Seyler</i> 370:343-352, Walter De Gruyter (1989)
	AT	<u>115</u>	Restifo, N.P., <i>et al.</i> , "Antigen Processing In Vivo and the Elicitation of Primary CTL Responses," <i>J. Immunol.</i> 154:4414-4422, American Association of Immunologists (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>116</u>	Saper, M.A., <i>et al.</i> , "Refined Structure of the Human Histocompatibility Antigen HLA-A2 at 2.6 Å Resolution," <i>J. Mol. Biol.</i> 219:277-319, Academic Press Ltd. (1991)
	AS	<u>116</u>	Schaeffer, E.B., <i>et al.</i> , "Relative contribution of 'determinant selection' and 'holes in the T-cell repertoire' to T-cell responses," <i>Proc. Natl. Acad. Sci. USA</i> 86:4649-4653, National Academy of Sciences (1989)
	AT	<u>116</u>	Schumacher, T.N.M., <i>et al.</i> , "Peptide selection by MHC class I molecules," <i>Nature</i> 350:703-706, Nature Publishing Group (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>117</u>	Sette, A., and Sidney, J., "HLA supertypes and supermotifs: a functional perspective on HLA polymorphism," <i>Curr. Opin. Immunol.</i> 10:478-482, Current Biology Publications (August 1998)
	AS	<u>117</u>	Sette, A., <i>et al.</i> , "A Novel Approach to the Generation of High Affinity Class II-Binding Peptides," <i>J. Immunol.</i> 145:1809-1813, American Association of Immunologists (1990)
	AT	<u>117</u>	Sette, A., <i>et al.</i> , "Effect of Conformational Propensity of Peptide Antigens in Their Interaction with MHC Class II Molecules," <i>J. Immunol.</i> 143:1268-1273, American Association of Immunologists (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>118</u>	Sette, A., <i>et al.</i> , "Peptide Binding to the Most Frequent HLA-A Class I Alleles Measured by Quantitative Molecular Binding Assays," <i>Mol. Immunol.</i> 31:813-822, Pergamon Press (1994)
	AS	<u>118</u>	Sidney, J., <i>et al.</i> , "Definition of an HLA-A3-Like Supermotif Demonstrates the Overlapping Peptide-Binding Repertoires of Common HLA Molecules," <i>Hum. Immunol.</i> 45:79-93, Elsevier Science Inc. (1996)
	AT	<u>118</u>	Sidney, J., <i>et al.</i> , "Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs," <i>Immunol. Today</i> 17:261-266, Elsevier Science (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>119</u>	Sidney, J., <i>et al.</i> , "The HLA-A*0207 Peptide Binding Repertoire is Limited to a Subset of the A*0201 Repertoire," <i>Hum. Immunol.</i> 58:12-20, Elsevier Science Inc. (November 1997)
	AS	<u>119</u>	Sinigaglia, F., and Hammer, J., "Defining rules for the peptide-MHC class II interaction," <i>Curr. Opin. Immunol.</i> 6:52-56, Current Biology Ltd. (1994)
	AT	<u>119</u>	Southwood, S., <i>et al.</i> , "Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires," <i>J. Immunol.</i> 160:3363-3373, American Association of Immunologists (April 1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>120</u>	Sprent, J., and Schaefer, M., "Properties of Purified T Cell Subsets. I. In Vitro Responses to Class I vs. Class II H-2 Alloantigens," <i>J. Exp. Med.</i> 162:2068-2088, Rockefeller University Press (1985)
	AS	<u>120</u>	Stark, J.M., <i>et al.</i> , "Immunogenicity of lipid-conjugated antigens. I. The Influence of Chain Length and Degree of Conjugation on Induction of Antibody in Mice," <i>Immunology</i> 39:345-352, Blackwell Scientific Publications (1980)
	AT	<u>120</u>	Steinman, R.M., "Dendritic cells and immune-based therapies," <i>Exp. Hematol.</i> 24:859-862, Elsevier Science Inc. (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>121</u>	Sudo, T., <i>et al.</i> , "Differences in MHC Class I Self Peptide Repertoires Among HLA-A2 Subtypes," <i>J. Immunol.</i> 155:4749-4756, American Association of Immunologists (1995)
	AS	<u>121</u>	Sugawara, S., <i>et al.</i> , "A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3," <i>J. Immunol. Methods</i> 100:83-90, Elsevier Science (1987)
	AT	<u>121</u>	Tam, J.P., and Lu, Y-A., "Vaccine engineering: Enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes," <i>Proc. Natl. Acad. Sci. USA</i> 86:9084-9088, National Academy of Sciences (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>122</u>	Townsend, A., and Bodmer, H., "Antigen Recognition by Class I-Restricted T Lymphocytes," <i>Ann. Rev. Immunol.</i> 7:601-624, Annual Reviews, Inc. (1989)
	AS	<u>122</u>	von Boehmer, H., and Haas, W., "Distinct Ir Genes for Helper and Killer Cells in the Cytotoxic Response to H-Y Antigen," <i>J. Exp. Med.</i> 150:1134-1142, Rockefeller University Press (1979)
	AT	<u>122</u>	Watari, E., <i>et al.</i> , "A Synthetic Peptide Induces Long-Term Protection from Lethal Infection with Herpes Simplex Virus 2," <i>J. Exp. Med.</i> 165:459-470, Rockefeller University Press (1987)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>123</u>	Wentworth, P.A., <i>et al.</i> , "In Vitro Induction of Primary, Antigen-Specific CTL from Human Peripheral Blood Mononuclear Cells Stimulated with Synthetic Peptides," <i>Mol. Immunol.</i> 32:603-612, Elsevier Science Ltd. (1995)
	AS	<u>123</u>	Wherry, E.J., <i>et al.</i> , "The Induction of Virus-Specific CTL as a Function of Increasing Epitope Expression: Responses Rise Steadily Until Excessively High Levels of Epitope Are Attained," <i>J. Immunol.</i> 163:3735-3745, American Association of Immunologists (October 1999)
	AT	<u>123</u>	Widmann, C., <i>et al.</i> , "T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides," <i>J. Immunol. Meth.</i> 155:95-99, Elsevier Science Publishers B.V. (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>124</u>	Wiesmüller, K-H., <i>et al.</i> , "Lipopeptide-Helper-T-Cell Epitope-CTL Epitope Conjugate Induces Antibodies Against the CTL Epitope," <i>Innovation Perspective Solid Phase Synthesis Collect. Papers, Int. Symp. 2nd</i> , pp. 499-502 (1991)
	AS	<u>124</u>	Wiesmüller, K-H., <i>et al.</i> , "Novel low-molecular-weight synthetic vaccine against foot-and mouth disease containing a potent B cell and macrophage activator," <i>Vaccine</i> 7:29-33, Butterworth & Co. (1989)
	AT	<u>124</u>	Yewdell, J.W., and Bennink, J.R., "Immunodominance in Major Histocompatibility Complex Class I-Restricted T Lymphocyte Responses," <i>Annu. Rev. Immunol.</i> 17:51-88, Annual Reviews Inc. (April 1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>125</u>	Zhou, X., <i>et al.</i> , "In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides," <i>J. Immunol. Methods</i> 153:193-200, Elsevier Science Publishers B.V. (1992)
	AS	<u>125</u>	Zinkernagel, R.M., <i>et al.</i> , "The Lymphoreticular System in Triggering Virus Plus Self-Specific Cytotoxic T Cells: Evidence for T Help," <i>J. Exp. Med.</i> 147:897-911, Rockefeller University Press (1978)
	AT	<u>125</u>	Altuvia, Y. <i>et al.</i> , "A Structure-Based Algorithm to Predict Potential Binding Peptides to MHC Molecules with Hydrophobic Binding Pockets," <i>Human Immunol.</i> 58:1-11, Elsevier Science Inc. (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SETTE *et al.*

Appl. No.: 09/350,401

Filed: July 8, 1999

For: **Inducing Cellular Immune
Responses to Hepatitis B Virus
Using Peptide and Nucleic Acid
Compositions**

Confirmation No.: 8008

Art Unit: 1644

Examiner: Schwadron, Ronald B.

Atty. Docket: 2060.0060008/PAJ/M-M

Third Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

In accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications AA100-AH100 cited on the attached Form PTO-1449 are not submitted. Copies of all other documents are provided.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

The documents cited in this Third Supplemental Information Disclosure Statement are of general relevance to the claimed invention.

This Information Disclosure Statement is being filed before the mailing of a first Office Action. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Peter A. Jackman
Attorney for Applicants
Registration No. 45,986

Date: April 11, 2005

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SETTE *et al.*

Appl. No.: 09/350,401

Filed: July 8, 1999

Confirmation No.: 8008

Art Unit: 1644

Examiner: Schwadron, Ronald B.

Atty. Docket: 2060.0060008/PAJ/M-M

For: **Inducing Cellular Immune
Responses to Hepatitis B Virus
Using Peptide and Nucleic Acid
Compositions**

Fourth Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

In accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, AA200-AI200, cited on the attached Form PTO-1449 are not submitted. Copies of all other documents are provided.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language document **AL200** cited on Form PTO-1449:

Document **AL200**, WO 81/00577, is in a foreign language. An English language abstract of document **AL200** is attached as document **AT209**.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

The documents cited in this Fourth Supplemental Information Disclosure Statement generally relate to hepatitis B virus (HBV).


This Information Disclosure Statement is being filed before the mailing of a first Office Action. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Peter A. Jackman
Agent for Applicants
Registration No. 45,986

Date: April 11, 2005

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

				Page 1 of 10		
FORM PTO-1449				ATTY. DOCKET NO. 2060.0060008/PAJ/M-M		
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICATION NO. 09/350,401		
FILING DATE July 8, 1999				ART UNIT 1644		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	FILING DATE
	AA200	4,428,941	01/31/1984	Galibert <i>et al.</i>		04/30/1981
	AB200	4,599,230	07/08/1986	Milich <i>et al.</i>		03/09/1984
	AC200	4,599,231	07/08/1986	Milich <i>et al.</i>		03/09/1984
	AD200	4,818,527	04/04/1989	Thornton <i>et al.</i>		12/09/1986
	AE200	4,882,145	11/21/1989	Thornton <i>et al.</i>		10/07/1987
	AF200	5,017,558	05/21/1991	Vyas		09/13/1983
	AG200	5,019,386	05/28/1991	Machida <i>et al.</i>		08/29/1988
	AH200	5,783,567	07/21/1998	Hedley <i>et al.</i>		01/22/1997
	AI200	5,840,303	11/24/1998	Chisari <i>et al.</i>		06/06/1995
	AJ					
	AK					
FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	TRANSLATION
	AL200	WO 81/00577 ✓	03/05/1981	WIPO		X Yes No
	AM200	EP 0 271 302 ✓	06/15/1988	Europe		Yes No
	AN200	EP 0 534 615 ✓	03/31/1993	Europe		Yes No
	AO200	WO 93/03753 ✓	03/04/1993	WIPO		Yes No
	AP200	WO 97/34621 ✓	09/25/1997	WIPO		Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)						
	AR	200	Alberti, A., <i>et al.</i> , "Antibody Response to Pre-S2 and Hepatitis B Virus Induced Liver Damage," <i>Lancet</i> 1:1421-1424, Lancet Publishing Group (1988)			
	AS	200	Barnaba, V., <i>et al.</i> , "Recognition of Hepatitis B Virus Envelope Proteins by Liver-Infiltrating T Lymphocytes in Chronic HBV Infection," <i>J. Immunol.</i> 143:2650-2655, American Association of Immunologists (1989)			
	AT	200	Bertoletti, A., <i>et al.</i> , "Molecular Features of the Hepatitis B Virus Nucleocapsid T-Cell Epitope 18-27: Interaction with HLA and T-Cell Receptor," <i>Hepatology</i> 26:1027-1034, Williams & Wilkins (1997)			
EXAMINER					DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.						

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>201</u>	Celis, E., <i>et al.</i> , "Recognition of Hepatitis B Surface Antigen by Human T Lymphocytes. Proliferative and Cytotoxic Responses to a Major Antigenic Determinant Defined by Synthetic Peptides," <i>J. Immunol.</i> 140:1808-1815, American Association of Immunologists (1988)
	AS	<u>201</u>	Cerny, A., <i>et al.</i> , "Induction <i>in vitro</i> of a primary human antiviral cytotoxic T cell response," <i>Eur. J. Immunol.</i> 25:627-630, VCH Verlagsgesellschaft (1995)
	AT	<u>201</u>	Ferrari, C., <i>et al.</i> , "Identification of Immunodominant T Cell Epitopes of the Hepatitis B Virus Nucleocapsid Antigen," <i>J. Clin. Invest.</i> 88:214-222, American Society for Clinical Investigation (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT****U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>202</u>	Hayashi, Y., <i>et al.</i> , "Studies on Peptides. CLXVI. Solid-Phase Syntheses and Immunological Properties of Fragment Peptides Related to Human Hepatitis B Virus Surface Antigen (HBsAg) and Its Pre-S2 Gene," <i>Chem. Pharm. Bull.</i> 36:4993-4999, Pharmaceutical Society of Japan (1988)
	AS	<u>202</u>	Hopp, T.P., "Immunogenicity of a Synthetic HBsAg Peptide: Enhancement by Conjugation to a Fatty Acid Carrier," <i>Mol. Immunol.</i> 21:13-16, Pergamon Press (1984)
	AT	<u>202</u>	Jolivet, M., <i>et al.</i> , "Polyvalent synthetic vaccines: relationship between T epitopes and immunogenicity," <i>Vaccine</i> 8:35-40, Butterworth & Co. (1990)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>203</u>	Kuhröber, A., <i>et al.</i> , "DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping K ^b - and K ^d -restricted epitopes," <i>Int. Immunol.</i> 9:1203-1212, Oxford University Press (1997)
	AS	<u>203</u>	Livingston, B.D., <i>et al.</i> , "Immunization with the HBV Core 18-27 Epitope Elicits CTL Responses In Humans Expressing Different HLA-A2 Supertype Molecules," <i>Hum. Immunol.</i> 60:1013-1017, Elsevier Science (November 1999)
	AT	<u>203</u>	Livingston, B.D., <i>et al.</i> , "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination are Comparable to Those Elicited by Acute Viral Infection," <i>J. Immunol.</i> 159:1383-1392, American Association of Immunologists (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>204</u>	Milich, D.R., "T- and B-cell recognition of hepatitis B viral antigens," <i>Immunol. Today</i> 9:380-386, Elsevier Science (1988)
	AS	<u>204</u>	Milich, D.R., and Chisari, F.V., "Immunogenetics and Cellular Correlates of the Immune Response to Hepatitis B Surface Antigen Determinants," in <i>Advances in Hepatitis Research</i> , Chisari, F.V., ed., Masson Publishing Co., New York, NY, pp. 91-109 (1984)
	AT	<u>204</u>	Missale, G., <i>et al.</i> , "HLA-A31- and HLA-Aw68-restricted Cytotoxic T Cell Responses to a Single Hepatitis B Virus Nucleocapsid Epitope during Acute Viral Hepatitis," <i>J. Exp. Med.</i> 177:751-762, Rockefeller University Press (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>205</u>	Moriyama, T., <i>et al.</i> , "Immunobiology and Pathogenesis of Hepatocellular Injury in Hepatitis B Virus Transgenic Mice," <i>Science</i> 248:361-364, American Association for the Advancement of Science (1990)
	AS	<u>205</u>	Nayersina, R., <i>et al.</i> , "HLA A2 Restricted Cytotoxic T Lymphocyte Responses to Multiple Hepatitis B Surface Antigen Epitopes During Hepatitis B Virus Infection," <i>J. Immunol.</i> 150:4659-4671, American Association of Immunologists (1993)
	AT	<u>205</u>	Neurath, A.R., <i>et al.</i> , "Specificity of Antibodies Elicited by a Synthetic Peptide Having a Sequence in Common with a Fragment of a Virus Protein—The Hepatitis B Surface Antigen," <i>Dev. Biol. Stand.</i> 54:103-112, S. Karger (1983)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>206</u>	Oseroff, C., <i>et al.</i> , "Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses," <i>Vaccine</i> 16:823-833, Elsevier Science (April 1998)
	AS	<u>206</u>	Rehermann, B., <i>et al.</i> , "Cytotoxic T Lymphocyte Responsiveness after Resolution of Chronic Hepatitis B Virus Infection," <i>J. Clin. Invest.</i> 97:1655-1665, American Society for Clinical Investigation (1996)
	AT	<u>206</u>	Rehermann, B., <i>et al.</i> , "The Cytotoxic T Lymphocyte Response to Multiple Hepatitis B Virus Polymerase Epitopes During and After Acute Viral Hepatitis," <i>J. Exp. Med.</i> 181:1047-1058, Rockefeller University Press (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>207</u>	Sällberg, M., <i>et al.</i> , "Human and Murine B-Cells Recognize the HBeAg/BETA (OR HBe2) Epitope as a Linear Determinant," <i>Mol. Immunol.</i> 28:719-726, Pergamon Press (1991)
	AS	<u>207</u>	Schulz, M., <i>et al.</i> , "Peptide-induced antiviral protection by cytotoxic T cells," <i>Proc. Natl. Acad. Sci. USA</i> 88:991-993, National Academy of Sciences (1991)
	AT	<u>207</u>	Sidney, J., <i>et al.</i> , "DRB1*0301 Molecules Recognize a Structural Motif Distinct from the One Recognized by Most DR β_1 Alleles," <i>J. Immunol.</i> 149:2634-2640, American Association of Immunologists (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>208</u>	Sobao, Y., <i>et al.</i> , "Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*2402, the most common HLA class I allele in East Asia," <i>J. Hepatol.</i> 34:922-929, Elsevier (2001)
	AS	<u>208</u>	van der Most, R.G., <i>et al.</i> , "Analysis of Cytotoxic T Cell Responses to Dominant and Subdominant Epitopes During Acute and Chronic Lymphocytic Choriomeningitis Virus Infection," <i>J. Immunol.</i> 157:5543-5554, American Association of Immunologists (1996)
	AT	<u>208</u>	Vitiello, A., <i>et al.</i> , "Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: implications on immunogenicity and immunodominance," <i>Eur. J. Immunol.</i> 27:671-678, VCH Verlagsgesellschaft (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

ATTY. DOCKET NO.
2060.0060008/PAJ/M-MAPPLICATION NO.
09/350,401**FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT**APPLICANT(S)
SETTE *et al.*FILING DATE
July 8, 1999ART UNIT
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>209</u>	Vitiello, A., <i>et al.</i> , "Development of a Lipopeptide-based Therapeutic Vaccine to Treat Chronic HBV Infection. I. Induction of a Primary Cytotoxic T Lymphocyte Response in Humans," <i>J. Clin. Invest.</i> 95:341-349, American Society for Clinical Investigation (1995)
	AS	<u>209</u>	Wentworth, P.A., <i>et al.</i> , "In Vitro Induction of Primary, Antigen-Specific CTL from Human Peripheral Blood Mononuclear Cells Stimulated with Synthetic Peptides," <i>Mol. Immunol.</i> 32:603-612, Pergamon Press (1995)
	AT	<u>209</u>	Derwent World Patent Index, English Abstract of WO 81/00577 (Document AL200), Dialog File Number 351, Accession No. 3160881

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.